21 May 2021MindMed (MNMD.Q) gets approval for groundbreaking mescaline studyTaylor Gavinchuk MNMD.Q In a groundbreaking story MindMed (MNMD.Q) announced today has been granted approval by the Swiss Ethics Committee to evaluate the acute effects of different doses of mescaline and the…